BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Cidara Therapeutics Stock Rises on Phase 3 Flu Treatment Trial
Cidara Therapeutics Stock Rises on Phase 3 Flu Treatment Trial
21
2
BTCCSquare news:
Cidara Therapeutics (CDTX) surged nearly 7% Friday after announcing the initiation of a Phase 3 trial for its investigational influenza treatment CD388. The non-vaccine preventive targets high-risk populations, with immunocompromised participants representing at least 10% of the study cohort.
The double-blind, placebo-controlled trial follows promising Phase 2b results. CD388's vaccine-independent mechanism offers potential advantages for patients with compromised immune systems or vaccine hesitancy. The timing coincides with heightened seasonal flu awareness, though the biotech's progress remains distinct from cryptocurrency market movements.
By:
